Barclays PLC Biomea Fusion, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Barclays PLC holds 39,620 shares of BMEA stock, worth $161,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,620

Previous 39,620 -0.0%

Holding current value

$161,649

Previous $401,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.23 - $10.1 $102,205 - $244,036	24,162 Added 156.31%	39,620 $401,000
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $129,826 - $479,792	-31,359 Reduced 66.98%	15,458 $70,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $354,277 - $496,294	-25,451 Reduced 35.22%	46,817 $699,000
Q4 2023 Feb 15, 2024	SELL	$8.37 - $19.8 $371,234 - $878,189	-44,353 Reduced 38.03%	72,268 $1.05 Million
Q3 2023 Nov 07, 2023	BUY	$13.44 - $23.02 $665,078 - $1.14 Million	49,485 Added 73.71%	116,621 $1.61 Million
Q2 2023 Aug 03, 2023	BUY	$21.66 - $41.8 $1.25 Million - $2.42 Million	57,907 Added 627.45%	67,136 $1.47 Million
Q1 2023 May 04, 2023	SELL	$6.8 - $32.35 $6,677 - $31,767	-982 Reduced 9.62%	9,229 $286,000
Q4 2022 Feb 13, 2023	BUY	$6.3 - $11.6 $56,473 - $103,982	8,964 Added 718.85%	10,211 $86,000
Q3 2022 Nov 03, 2022	BUY	$9.51 - $13.61 $2,700 - $3,865	284 Added 29.49%	1,247 $12,000
Q2 2022 Aug 12, 2022	SELL	$3.0 - $12.03 $10,566 - $42,369	-3,522 Reduced 78.53%	963 $12,000
Q1 2022 May 16, 2022	BUY	$4.39 - $9.03 $19,689 - $40,499	4,485 New	4,485 $20,000

Others Institutions Holding BMEA

# of Institutions

104

Shares Held

17.8M

Call Options Held

1.68M

Put Options Held

410K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $120M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account